These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33152414)

  • 1. Impact of ischemic risk factors on long-term outcomes in patients with and without high bleeding risk.
    Shima Y; Miura K; Shimada T; Ohya M; Murai R; Kubo S; Tada T; Tanaka H; Fuku Y; Kadota K
    Int J Cardiol; 2021 Mar; 326():12-18. PubMed ID: 33152414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
    Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
    BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
    Sorrentino S; Claessen BE; Chandiramani R; Guedeney P; Vogel B; Baber U; Rau V; Wang J; Krucoff M; Kozuma K; Ge J; Seth A; Makkar R; Liu Y; Bangalore S; Bhatt DL; Angiolillo DJ; Saito S; Neumann FJ; Hermiller J; Valgimigli M; Mehran R
    Circulation; 2020 Mar; 141(11):891-901. PubMed ID: 31992063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
    Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C
    Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents.
    Goel R; Cao D; Chandiramani R; Roumeliotis A; Blum M; Bhatt DL; Angiolillo DJ; Ge J; Seth A; Saito S; Krucoff M; Kozuma K; Makkar RM; Bangalore S; Wang L; Koo K; Neumann FJ; Hermiller J; Stefanini G; Valgimigli M; Mehran R
    Catheter Cardiovasc Interv; 2021 Nov; 98(6):1111-1119. PubMed ID: 33038061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
    Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies.
    Chandiramani R; Cao D; Claessen BE; Sorrentino S; Guedeney P; Blum M; Goel R; Roumeliotis A; Krucoff M; Kozuma K; Ge J; Seth A; Makkar R; Bangalore S; Bhatt DL; Angiolillo DJ; Ruster K; Wang J; Saito S; Neumann FJ; Hermiller J; Valgimigli M; Mehran R
    J Am Heart Assoc; 2020 Apr; 9(7):e014611. PubMed ID: 32223396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal variations in ischemic and bleeding event risks after acute coronary syndrome during dual antiplatelet therapy.
    Fujii T; Kasai S; Kawamura Y; Yoshimachi F; Ikari Y
    Int J Cardiol; 2023 Dec; 392():131340. PubMed ID: 37678433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
    Gajanana D; Rogers T; Weintraub WS; Kolm P; Iantorno M; Khalid N; Chen Y; Shlofmitz E; Khan JM; Musallam A; Ben-Dor I; Satler LF; Zhang C; Torguson R; Waksman R
    Am J Cardiol; 2020 Jun; 125(11):1631-1637. PubMed ID: 32273057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study.
    Hioki H; Kozuma K; Kinoshita Y; Nanasato M; Ito Y; Yamaguchi J; Shiode N; Hibi K; Tanabe K; Ako J; Morino Y; Hirohata A; Sonoda S; Nakagawa Y; Okada H; Nakagami T; Takamisawa I; Ando K; Abe M; Ikari Y
    J Cardiol; 2021 Aug; 78(2):107-113. PubMed ID: 33875313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison and Validation of Long-Term Bleeding Events for Academic Bleeding Risk (ARC-HBR) Criteria and Contemporary Risk Scores for Percutaneous Coronary Intervention With a Second-Generation Drug Eluting Stent.
    Okabe K; Miura K; Shima Y; Ikuta A; Taguchi Y; Takahashi K; Osakada K; Ohya M; Kubo S; Tada T; Tanaka H; Fuku Y; Kadota K
    Circ J; 2022 Aug; 86(9):1379-1387. PubMed ID: 35400715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 6- versus 12-month dual antiplatelet therapy on clinical prognosis in patients with high bleeding risk: Insights from the 4-year results of the I LOVE IT 2 study.
    Zhang J; Qiu M; Na K; Ma S; Jiang Z; Li J; Li Y; Han Y
    Catheter Cardiovasc Interv; 2021 May; 97 Suppl 2():1025-1031. PubMed ID: 33645914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ischemic and Bleeding Events in PENDULUM Patients With High Bleeding Risk and High Platelet Reactivity.
    Iijima R; Kadota K; Nakao K; Nakagawa Y; Shite J; Yokoi H; Kozuma K; Tanabe K; Akasaka T; Shinke T; Ueno T; Hirayama A; Uemura S; Harada A; Kuroda T; Takita A; Murakami Y; Saito S; Nakamura M
    Circ J; 2022 Apr; 86(5):763-771. PubMed ID: 34880154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study.
    Wang HY; Wang Y; Yin D; Gao RL; Yang YJ; Xu B; Dou KF
    J Interv Cardiol; 2020; 2020():2985435. PubMed ID: 32405273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    Cardiovasc Interv Ther; 2021 Jan; 36(1):91-103. PubMed ID: 32086787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the Academic Research Consortium for High Bleeding Risk Criteria and Prognostic Value of a Simplified Definition.
    Miura K; Shimada T; Ohya M; Murai R; Amano H; Kubo S; Tada T; Tanaka H; Fuku Y; Goto T; Kadota K
    Circ J; 2020 Aug; 84(9):1560-1567. PubMed ID: 32669530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.